Myostatin

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 27, 2024
Research, Neurodegenerative disease, Notifiable disease, LDL, Obesity, University, Comparison, PCSK9, Central Florida, Translational research, COVID-19, PD, CSF, Diabetes, Amprion, Patient, CNS, Mayo Clinic, Vaccine, Journal, Biomarker, Travel, Myostatin, Hope, SARS-CoV-2, D&O, Investment, Solid lipid nanoparticle, MDS, Marketing, Parkinson's disease, Hypercholesterolemia

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • We also seek to advance UB-311, our anti-Aβ Alzheimer’s candidate, as we resume dialogue with regulatory authorities and partners.
  • General and administrative expenses were $3.4 million and $7.7 million for the three months ended December 31, 2023, and 2022, respectively.
  • General and administrative expenses were $22.4 million and $28.4 million for the years ended December 31, 2023, and 2022, respectively.

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, March 19, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Overweight, SMN, Conference, Obesity, Keystone, MDA, Gilead Sciences, SAPPHIRE, SMA, Manuscript, Myostatin, Rock, Muscular dystrophy, Muscular Dystrophy Association, Trial of the century, Efficacy, Clinical trial, Therapy, Literature, Lunch, Pharmaceutical industry

“In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are poised for a transformational year ahead.

Key Points: 
  • “In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are poised for a transformational year ahead.
  • Scholar Rock remains on track to report topline data from the Phase 3 trial in the fourth quarter of 2024.
  • Scholar Rock also presented a literature review that describes the ongoing burden and significant unmet needs in SMA despite advancements in treatment.
  • Dr. Qatanani joined Scholar Rock in 2021 and has been leading all research functions since 2022 and driving Scholar Rock’s early-stage pipeline, including SRK-439.

Physicians Lab Launches the First-of-Its-Kind At-Home Lab Test for Myostatin and Follistatin Levels

Retrieved on: 
Wednesday, March 13, 2024
Growth, B cell, Regeneration, Follistatin, Inflammation, Patient, Myostatin, Weight loss, Research, ELISA, Reproduction, TGF, Medicine, Physician, Collection, Blood, Medical imaging

BOCA RATON, Fla., March 13, 2024 /PRNewswire/ -- Physicians Lab, a provider of at-home lab testing for integrative medicine and wellness, launched a new at-home lab test that measures the analytes myostatin and follistatin.  The test will show the current myostatin and follistatin levels and the ratio of myostatin to follistatin.  The new test will be useful for monitoring muscle loss or growth in individuals.

Key Points: 
  • BOCA RATON, Fla., March 13, 2024 /PRNewswire/ -- Physicians Lab, a provider of at-home lab testing for integrative medicine and wellness, launched a new at-home lab test that measures the analytes myostatin and follistatin.
  • The test will show the current myostatin and follistatin levels and the ratio of myostatin to follistatin.
  • Our team is excited to expand Physicians Lab solutions and to offer this at-home lab test to integrative providers and directly to health-conscious consumers."
  • To determine the values of myostatin and follistatin, Physicians Lab uses a high-sensitivity Enzyme-Linked Immunosorbent Assay (ELISA) technique.

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Fitness & Nutrition, Pharmaceutical, Clinical Trials, Poster, Weight loss, Pharmacokinetics, Human, Investigational New Drug, Obesity, Patient, IND, Fasting, Keystone, Myostatin, GDF11, Mouse, Rock, MPH, Food, SMA, Body composition, Immunoglobulin G, Nandi (Hinduism), Doctor of Philosophy, Liraglutide, ELISA, Dietary supplement

“These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.

Key Points: 
  • “These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.
  • “We believe that preserving lean muscle mass through our highly selective approach to myostatin inhibition in combination with GLP-1 RA therapy has the potential to transform the management of weight loss.
  • In parallel, Scholar Rock is developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity.
  • SRK-439 also improved fat mass loss (–36.60% to –46.32% from baseline with semaglutide; –17.31% to –19.04% from baseline with liraglutide).

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Retrieved on: 
Tuesday, January 23, 2024
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Obesity, Patient, Rock, Weight loss, Myostatin, IND, Food, Safety, Investigational New Drug, MPH, SMA, Overweight, Pharmaceutical industry

The Phase 2 trial is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of apitegromab, a highly selective myostatin inhibitor, to safely preserve lean muscle mass as an adjunctive therapy in overweight and obese adults who are taking a GLP-1 RA.

Key Points: 
  • The Phase 2 trial is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of apitegromab, a highly selective myostatin inhibitor, to safely preserve lean muscle mass as an adjunctive therapy in overweight and obese adults who are taking a GLP-1 RA.
  • Trial initiation is on track for mid-2024, and data from the apitegromab Phase 2 trial are expected in mid-2025.
  • In parallel, Scholar Rock is developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity.
  • The Company plans to file an IND for SRK-439 in 2025.

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024
Research, Neurology, Diabetes, Clinical Trials, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Conference, Cure, IND, SAPPHIRE, Spinal muscular atrophy, Clinical trial, Obesity, Standard of care, Annual general meeting, Gongshi, Consequence, Myostatin, DRAGON, Webcast, MPH, Patient, Rock, SMN, SMA, Renal cell carcinoma, SITC, Pharmaceutical industry

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
  • Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
  • Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Keros Therapeutics to Develop KER-065 for the Treatment of Obesity

Retrieved on: 
Wednesday, January 3, 2024
Protein, Research, Weight, Prevalence, Weight loss, KROS, Mouse, Therapy, Ligand, Conditional sentence, Obesity, Myostatin, Frailty, Patient, Facial muscles, Disorder, GDF8, Dietary supplement

“Obesity is a complex and chronic disease associated with numerous comorbidities and a growing prevalence in patients.

Key Points: 
  • “Obesity is a complex and chronic disease associated with numerous comorbidities and a growing prevalence in patients.
  • We believe there is a need for additional treatment options, including one that leads to weight loss without an associated loss of muscle and a potential for frailty.
  • RKER-065 and RKER-034 had equivalent increases in skeletal muscle in the diet-induced obesity (“DIO”) mouse model.
  • Based on this preclinical data, Keros believes that KER-065 has the potential to treat obesity both as a monotherapy and in combination with GLP-1 RA by increasing muscle mass and decreasing fat mass.

Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, November 7, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Gongshi, Myostatin, SMN, SAPPHIRE, IND, PIN, MPH, Obesity, Pembrolizumab, Maintenance, SITC, Rock, DRAGON, Clinical trial, Neoplasm, Webcast, Annual general meeting, ORR, Renal cell carcinoma, SMA, Patient, Pharmaceutical industry, Cryptocurrency

The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.

Key Points: 
  • The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.
  • Research and development expense was $30.3 million for the quarter ended September 30, 2023, compared to $33.4 million for the quarter ended September 30, 2022.
  • General and administrative expense was $13.3 million for the quarter ended September 30, 2023, compared to $10.5 million for the quarter ended September 30, 2022.
  • A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Fortetropin Identified as Potential Solution for Muscle Loss Linked to Popular Weight Loss Products

Retrieved on: 
Thursday, October 19, 2023
Facial muscles, Myostatin, American College, Yolk, History of the University of California, Berkeley, Duke University, McMaster University, Weight loss, Atrophy, University of California, Berkeley, Research, Journal, Athlete, Metabolism, Leg, University, PLOS One, Immobilization, Woman, Weight, Appetite, Dietary supplement, CORP

CEDAR KNOLLS, N.J., Oct. 19, 2023 /PRNewswire-PRWeb/ --

Key Points: 
  • Preliminary observations by esteemed experts suggest that Fortetropin might be a promising solution to the muscle deterioration linked with certain mainstream weight loss products.
  • However, like many weight loss products, it can lead to muscle loss.
  • By combining a muscle health product like Fortetropin with a weight loss product, users should enjoy the weight loss benefits without the same degree of muscle depletion.
  • This suggests that Fortetropin supplementation can favor a conducive environment for muscle growth and as well as attenuate muscle loss.

Scholar Rock to Advance Antimyostatin Program to Develop Novel Therapies for Cardiometabolic Disorders

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Cardiovascular disease, Senior, Cancer, Obesity, Weight loss, IND, SAPPHIRE, Rock, Myostatin, Type 2 diabetes, Facial muscles, Maintenance, Clinical trial, Mace Head Atmospheric Research Station, SMA, Patient, Pharmaceutical industry, Vaccine, Gongshi, Research

Data from the clinical trial are expected in mid-2025 and will be used to inform further clinical development of SRK-439.

Key Points: 
  • Data from the clinical trial are expected in mid-2025 and will be used to inform further clinical development of SRK-439.
  • “As a long-standing leader in targeting myostatin with a highly selective antibody platform, we are excited to advance our cardiometabolic program.
  • Leveraging proven expertise in antimyostatin and its effect on increasing muscle mass, the Company has been developing myostatin-selective inhibitors to address cardiometabolic disorders, including obesity.
  • The Company believes the selectivity of these antibody candidates enables a favorable risk-benefit profile for patients with cardiometabolic disorders.